camel milk and type 2 diabetes

Effect of camel milk on blood sugar, insulin resistance, lipid profile and blood pressure in type 2 diabetic patients.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201302044794N7

Enrollment

Registered

2013-02-18

Start date

2012-12-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Intervention group: camel milk, 500 ml/day. Intervention 2: Intervention group: camel dough, 500 ml/day. Intervention 3: Control group: cow milk, 500 ml/day.

Placebo

Intervention group: camel milk, 500 ml/day

Intervention group: camel dough, 500 ml/day

Control group: cow milk, 500 ml/day

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Patients with type 2 diabetes; age range: 20 to 70 years old; treatment with diet or oral anti-diabetic drugs. Exclusion Criteria: Treatment with insulin; pregnancy or lactation; smoking and alcohol consumption; body mass index greater than 35 kg/m2 ; Lactose intolerance; taking estrogenic drugs and corticosteroids; having cardiovascular disease, liver, lung, kidney and Chronic gastrointestinal and thyroid dysfunction; following from the weight loss diets two months prior to study; weight changes (increase or decrease) more than 5 kg two months prior to study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fasting blood glucose. Timepoint: Baseline, after 1 month, and after 2 months. Method of measurement: Biochemical analysis.;Hemoglobin A1c. Timepoint: Baseline, and after 2 months. Method of measurement: Biochemical analysis.;Insulin resistance. Timepoint: Baseline, after 1 month, and after 2 months. Method of measurement: HOMA-IR index.;Blood pressure. Timepoint: Baseline, after 1 month, and after 2 months. Method of measurement: sphygmomanometer.;Lipid profile: total cholesterol, Triglyceride, HDL, LDL. Timepoint: Baseline, after 1 month, and after 2 months. Method of measurement: Biochemical analysis.	—

Measure

Time frame

Fasting blood glucose. Timepoint: Baseline, after 1 month, and after 2 months. Method of measurement: Biochemical analysis.;Hemoglobin A1c. Timepoint: Baseline, and after 2 months. Method of measurement: Biochemical analysis.;Insulin resistance. Timepoint: Baseline, after 1 month, and after 2 months. Method of measurement: HOMA-IR index.;Blood pressure. Timepoint: Baseline, after 1 month, and after 2 months. Method of measurement: sphygmomanometer.;Lipid profile: total cholesterol, Triglyceride, HDL, LDL. Timepoint: Baseline, after 1 month, and after 2 months. Method of measurement: Biochemical analysis.

—

Secondary

Measure	Time frame
Dietary Factors. Timepoint: Baseline, after 1 month, and after 2 months. Method of measurement: 24h dietary recall.;Body mass index. Timepoint: Baseline, after 1 month, and after 2 months. Method of measurement: Anthropometric measurements.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFereidoun Azizi

Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences

azizi@endocrine.ac.ir+98 21 2243 2500

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026